MiCareo Taiwan Co., Ltd.
4
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 4 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System
Role: lead
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
Role: lead
Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients
Role: lead
Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer
Role: lead
All 4 trials loaded